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ABSTRACT
Recurrent acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HSCT) predicts a
dismal prognosis. We sought to determine whether a second HSCT would result in long-term disease-free
survival with acceptable toxicity. We evaluated the outcome of a second HSCT with a preparative regimen of
cyclophosphamide and total body irradiation in pediatric patients with AML who relapsed after an initial HSCT
with a busulfan and cyclophosphamide preparative regimen. Twenty-five patients aged 1.1 to 17.2 years
(median, 4.1 years) with AML received a second HSCT for recurrent disease. All patients were conditioned
with busulfan and cyclophosphamide for the first HSCT and with cyclophosphamide and total body irradiation
for the second HSCT. Donor sources for the first HSCT were autologous (n  11) or allogeneic (n  14),
whereas all donors for the second HSCT were allogeneic (12 matched related, 9 mismatched related, and 4
unrelated). Engraftment after the second HSCT occurred in all patients at median of 19.0 days (range, 11-32
days). The cumulative incidence of grade II to IV graft-versus-host disease was 76% after the second HSCT.
Three patients died from regimen-related toxicity before day 100, 9 relapsed at a median of 5.4 months (range,
1.8-34.0 months), and 12 survived a median of 9.1 years (range, 7.0-14.4 years) after the second HSCT. The
Kaplan-Meier estimates of survival at 100 days, 1 year, and 10 years were 88%, 56%, and 48%, respectively.
The disease-free survival rate at 10 years was 44%. Multivariate Cox regression analysis suggested that patients
who received a second HSCT in relapse had a relative risk of relapse of 7.8 (P  .02) compared with patients
who underwent transplantation in remission. In addition, patients who received their second HSCT <6
months after the first transplantation were at increased risk of relapse (P .03). These data suggest that second
HSCT after a failed initial transplantation results in long-term disease-free survival in one half of children with
relapsed AML. Because a higher tumor burden at the time of second HSCT was associated with a higher risk
of subsequent relapse, patients might benefit from reinduction therapy before the second HSCT.
© 2003 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Despite advances in the treatment of pediatric
cute myeloid leukemia (AML), postinduction relapse
emains the major cause of treatment failure [1-8].
ematopoietic stem cell transplantation (HSCT) has
igniﬁcantly contributed to the improved outcome for
ediatric AML, but posttransplantation relapse occurs
n 20% to 60% of patients [9-11]. Treatment options06or patients who relapse after HSCT are limited. Re-
nduction chemotherapy and donor lymphocyte infu-
ion may result in complete remission in a proportion
f these patients, but few, if any, are likely to be cured
ith this approach [12-14]. Second HSCT for re-
apsed leukemia, with limited success, has been previ-
usly described in adult AML [15-18]. In these stud-
es, an extremely high rate of transplant-relatedoi:10.1016/j.bbmt.2003.08.003
mortality was the major cause of treatment failure.
However, these observations may not apply to the
pediatric population. In a previous study of 77 adult
and pediatric patients undergoing a second marrow
HSCT for recurrent leukemia, we demonstrated that
a severe regimen-related mortality of 39% limited the
overall disease-free survival (DFS) to 16% [19]. In
contrast to the adult patients, the 19 pediatric patients
in the study had a signiﬁcantly lower regimen-related
mortality. DFS for the 9 AML patients in this study
was 44%. These data suggested that second HSCT
may be an option in young patients with AML. This
study examines the outcome for 25 patients 18 years
of age with recurrent AML after an initial HSCT with
a busulfan (BU) and cyclophosphamide (CY) prepar-
ative regimen and who received a second HSCT with
a CY and total body irradiation (TBI) preparative
regimen.
MATERIALS AND METHODS
Patients
All patients 18 years of age with AML who
received an initial HSCT with a preparative regimen
of BU 16 mg/kg and CY 200 mg/kg, relapsed, and
received a second HSCT with a preparative regimen
of CY 120 mg/kg plus TBI (1200-1575 cGy) were
included. The 25 patients who met these entry criteria
received their second HSCT at the Fred Hutchinson
Cancer Research Center (FHCRC; Seattle, WA). Ini-
tial HSCT between October 1986 and May 1997 was
performed at FHCRC for 16 patients and at other
centers for 9 patients. Results were analyzed as of
October 1, 2002. One patient was previously reported
[19].
Donors, Conditioning Regimens, and
Graft-versus-Host Disease Prophylaxis
First HSCT. All patients received an initial BU/CY
preparative regimen that was composed of BU 1
mg/kg every 6 hours for 4 days (days 9 to 6) and
CY 50 mg/kg for 4 days (days 5 to 2). Donor
marrow was infused on day 0. Among the 16 patients
whose initial HSCT was at FHCRC, 11 received
matched related donor marrow allografts, and 5 re-
ceived autografts. Of the 9 patients who initially un-
derwent transplantation at other institutions, 6 re-
ceived autografts and 3 received marrow from
matched related donors. In total, 11 patients received
autografts, 11 received matched related allografts, and
3 received 1 antigen–mismatched related allografts.
Graft-versus-host disease (GVHD) prophylaxis
for the initial HSCT varied by the transplant center.
Of the 11 patients who received allogeneic HSCT at
FHCRC, 9 received long methotrexate (MTX), and 3
received MTX plus cyclosporine (CSA). Of the 3
patients who received allogeneic HSCT in other in-
stitutions, 1 received long MTX, 1 received MTX plus
CSA, and 1 received T cell–depleted marrow and
MTX.
Relapse was deﬁned as morphologic or cytoge-
netic recurrence of histologically or cytogenetically
similar leukemia in the marrow or in the central ner-
vous system (CNS). The median time from the initial
HSCT to relapse was 6.2 months (range, 0.7-43.8
months). Twenty patients had isolated bone marrow
relapse (19 in morphologic and 1 in cytogenetic re-
lapse), 1 patient had an isolated CNS relapse, and 4
patients had combined marrow and extramedullary
relapse (2 with CNS, 1 with palpebral chloroma, and
1 with leukemic inﬁltration of the pancreas).
Intensive systemic reinduction chemotherapy with
a regimen that contained high-dose cytarabine was
attempted in 16 of 25 patients, and 1 patient received
low-dose oral chemotherapy while awaiting transplan-
tation. Local CNS therapy (intrathecal chemotherapy
with or without cranial irradiation) was given to 3
patients: 1 with isolated CNS relapse and 2 with com-
bined marrow and CNS relapse. Reinduction was not
attempted in 5 patients: 4 in morphologic relapse and
1 in cytogenetic relapse. At the time of second HSCT,
10 patients were in remission and 15 were in relapse.
Second HSCT. The median time between the ﬁrst
and second HSCT was 9.6 months (range, 1.8-46.1
months). The preparative regimens for the second
transplantation included CY 60 mg/kg/d for 2 days,
followed by one of several previously described TBI
regimens [20-22]. The TBI regimen was fractionated
and delivered at 1575 cGy (n  12) or 1350 cGy (n 
3) or was hyperfractionated and delivered at 1440 cGy
(n  10). Two patients with mismatched donors also
received horse antithymocyte globulin (Upjohn,
Kalamazoo, MI) at a dose of 30 mg/kg for 3 doses.
Bone marrow was collected according to established
methods [21,23] and was infused through a central
venous catheter on day 0, within 24 hours from the
last dose of irradiation. GVHD prophylaxis was MTX
with or without CSA in 24 patients and T-cell deple-
tion in 1 patient. The choice of GVHD prophylaxis
was based on the protocol active at the time the
patients were being treated. Donors were matched
related (n  12), mismatched related (n  9), or
unrelated (n  4). Related donor-recipient pairs were
HLA-mismatched for 1 antigen (n  6), 2 antigens
(n  1), or 3 antigens (n  2), and unrelated donor-
recipient pairs were HLA minor-mismatched at the B
antigen (n  3).
All protocols and consents were approved by the
Institutional Review Board of the FHCRC. The pro-
cedures, along with the risks and beneﬁts, were ex-
plained in detail to patients, parents, and donors, and
informed consent was obtained.
All patients had indwelling central venous cathe-
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ters. Nutritional support was provided by hyperali-
mentation. Measures to prevent infection varied ac-
cording to the standard of practice at the time of
HSCT but included prophylactic ﬂuconazole [24,25]
and ganciclovir for cytomegalovirus (CMV) prophy-
laxis [26,27], as well as the use of single conventional
or laminar airﬂow rooms, growth factors, and intra-
venous immunoglobulin G.
HLA Typing and Engraftment
Histocompatibility testing was performed by the
clinical immunogenetics laboratory at FHCRC for all
patients and donors as described previously [28]. En-
graftment was deﬁned by achievement of a peripheral
granulocyte count of500/L for 3 consecutive days.
For allogeneic recipients, donor engraftment was de-
termined by in situ DNA hybridization with a Y chro-
mosome–speciﬁc probe [29] for sex-mismatched
HSCT, by restriction fragment length polymorphism
analysis [30], or, for sex-matched HSCT, by polymer-
ase chain reaction assay of genomic DNA for variable
number of tandem repeats [31].
Regimen-Related Toxicity, GVHD, and Quality of
Life Determination
Regimen-related toxicity (RRT), including veno-
occlusive disease (VOD), was scored with the method
of Bearman et al. [32]. Acute and chronic GVHDwere
diagnosed according to conventional criteria and
treated as previously described [33-35]. Quality of life
was evaluated by using the Lansky Play Performance
Scale [36] or Karnofsky performance status [37] re-
sults reported by parents, guardians, or physicians on
an annual basis.
Statistical Analysis
Time-to-event end points were evaluated from the
time of second HSCT until the minimum time of the
event of interest, date of last contact (censoring), or
competing risk event (where applicable). Probabilities
of relapse and nonrelapse mortality (NRM) were cal-
culated by using cumulative incidence estimates, treat-
ing death before relapse and relapse as competing risk
events, respectively [38]. Kaplan-Meier estimates were
used to evaluate probabilities of survival and DFS [39].
The effects of candidate prognostic factors were as-
sessed on each of the clinical outcomes by using uni-
variate and multivariate Cox proportional hazards re-
gression. When DFS was the outcome of interest, a
composite end point of death or relapse was used in
the model. Because of the small number of patients in
this study, no more than 2 risk factors could be reli-
ably assessed together in the same model. Two-sided
P values .05 were considered statistically signiﬁcant.
RESULTS
Patient characteristics, including age at transplan-
tation, disease phase, preparative regimen, and donor
characteristics, are presented in Table 1.
Engraftment and RRT
Engraftment occurred at a median of 19 days
(range, 11-32 days). There were no graft rejections or
late graft failures. For most patients, RRT was mild
(Table 2). Grade 3 or 4 RRT was seen in only 2
patients (8%), both of whom developed hepatic tox-
icity. The 2 patients with RRT involving the liver died
of hepatic VOD before day 100. One patient had
experienced transient hyperbilirubinemia, increased
transaminases, and mild VOD after the ﬁrst transplan-
tation and had increased transaminases plus a histo-
logical diagnosis of nonspeciﬁc hepatitis immediately
before the second transplantation. The second patient
experienced no liver toxicity after the ﬁrst transplan-
Table 1. Patient Characteristics for First and Second HSCT
Variable First HSCT Second HSCT
Median age, y (range) 3.9 (0.4–16.4) 4.1 (1.1–17.2)
Disease phase at HSCT (n  25)
Remission, n (%) 18 (72) 10 (40)
Relapse, n (%) 7 (28) 15 (60)
Preparative regimen
BU/CY, n (%) 25 (100) 0 (0)
CY/TBI, n (%) 0 (0) 25 (100)
Donor
Autologous, n (%) 11 (44) 0 (0)
MRD, n (%) 11 (44) 12 (48)
MMRD, n (%) 3 (12) 9 (36)
URD, n (%) 0 (0) 4 (16)
GVHD prophylaxis
MTX, n (%) 10 (40) 11 (44)
MTX/CSP, n (%) 3 (12) 13 (52)
T-Cell depletion, n (%) 1 (4) 1 (4)
None, n (%) 11 (44) 0 (0)
BU indicates busulfan; CY, cyclophosphamide; TBI, total body
irradiation; MRD, matched related donor; MMRD, mismatched
related donor; URD, unrelated donor; MTX, methotrexate;
CSP, cyclosporine.
Table 2. Regimen-Related Toxicity by Organ System after Second HSCT
Organ System
Grade 0 Grade 1–2 Grade 3–4
n % n % n %
Cardiac 22 88 3 12 0 0
Bladder 21 84 4 16 0 0
Renal 21 84 3 12 1 4
Pulmonary 23 92 2 8 0 0
Hepatic 16 64 7 28 2 8
Mucositis 0 0 25 100 0 0
Gastrointestinal 15 60 8 32 2 8
Skin 11 44 14 56 0 0
S. Meshinchi et al.
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tation but developed both grade IV GVHD and pre-
sumed hepatic VOD after the second transplantation.
Graft-versus-Host Disease. Acute GVHD developed
in 19 of 25 evaluable patients at a median of 17 days
(range, 5-70 days) after the second HSCT. The cu-
mulative incidence of grade II to IV acute GVHD
after the second HSCT was 76%. Five patients devel-
oped grade III or IV acute GVHD. Four of these 5
patients had mismatched donors (3 mismatched re-
lated and 1 mismatched unrelated). Of the 6 patients
with grade 0 or I GVHD, 5 had matched related
donors. There was no grade III or IV GVHD after the
ﬁrst HSCT. Four (29%) of the 14 patients who had
allogeneic donors for the ﬁrst HSCT developed grade
II acute GVHD. Of these 4 patients with grade II
GVHD after the ﬁrst HSCT, 2 developed grade III
and IV acute GVHD after the second HSCT from the
same donors. One patient, who developed extensive
chronic GVHD after the ﬁrst HSCT, had persistent
chronic GVHD, did not develop acute GVHD, and
relapsed and died of progressive disease with chronic
GVHD after the second HSCT. Ten of 21 evaluable
patients developed clinical extensive chronic GVHD.
Clinical Outcome. Overall survival (OS) 10 years
after the second HSCT was 48% (Figure 1), with a
DFS of 44% (Table 3), for all patients. Patients who
relapsed after the second HSCT died of progressive
disease, with the exception of 1 patient, who had an
isolated relapse in the orbit with no marrow involve-
ment 5 months after second HSCT. That patient
received systemic chemotherapy and focal irradiation
to the orbit and is alive more than 14 years after the
isolated extramedullary relapse. The relapse rate (RR)
and NRM 10 years after the second HSCT were 36%
and 20%, respectively (Figure 1). DFS for patients
who underwent transplantation in remission was 70%,
compared with 27% for those who underwent trans-
plantation in relapse (P  .05; Figure 2 and Table 3).
Patients who received an initial autologous transplant
had better survival than allogeneic transplant recipi-
ents, although this difference did not reach statistical
signiﬁcance (64% versus 36%; P  .22; Table 3).
Eleven patients had an initial autologous HSCT, of
whom 5 were in remission and 6 were in relapse at the
time of the second HSCT. OS for the autologous
HSCT recipients was 64% (7/11); the 5 patients who
underwent transplantation in remission had an OS of
80% (4/5), compared with 50% (3/6) for those who
underwent transplantation in relapse. Fourteen pa-
tients received an initial allogeneic HSCT, of whom 5
underwent transplantation in remission and 9 in re-
lapse. The OS for initial allogeneic HSCT recipients
as a group was 36% (5/14); the 5 patients who under-
went transplantation in remission had an OS of 60%
Figure 1. Kaplan-Meier estimates for overall survival, relapse mor-
tality, and nonrelapse mortality from second HSCT for all patients.
Table 3. NRM, Relapse, and Outcome at 10 Years after Second HSCT
Variable NRM* Relapse DFS† Survival†
Overall 0.20 0.36 0.44 0.48
Donor type at second
transplant
MRD 0.17 0.42 0.42 0.50
MMRD 0.22 0.33 0.44 0.44
URD 0.25 0.25 0.50 0.50
P value† .88 .91 .91 .86
Donor type at first
transplant
Autologous 0.09 0.27 0.64 0.64
Allogeneic 0.29 0.43 0.29 0.36
P value‡ .22 .36 .14 .22
Phase at second
transplantation
Remission 0.20 0.10 0.70 0.70
Relapse 0.20 0.53 0.27 0.33
P value‡ .83 .02 .05 .10
Time from first to second
transplant
>6 mo 0 0.80 0.20 0.40
<6 mo 0.25 0.25 0.50 0.50
P value‡ .32 .03 .21 .71
*Cumulative incidence estimates.
†Kaplan-Meier estimates.
‡Two-sided P value from the likelihood ratio test.
Figure 2. Kaplan-Meier estimates for disease-free survival from
second HSCT for patients who underwent transplantation in re-
mission versus relapse. P  0.05.
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(3/5), compared with 22% (2/9) for those who under-
went transplantation in relapse.
Relapse, NRM, and Cause of Death. The cumulative
incidence of relapse was 36% (Figure 1), with 9 pa-
tients relapsing at a median of 0.5 years (range, 0.2-2.8
years). Among the 8 patients who died of relapse, the
median time to death due to relapse was 0.6 years,
with a range of 0.3 to 3.5 years. Patients who under-
went transplantation in remission had an RR of 10%,
compared with 53% in patients who underwent trans-
plantation in relapse (P  .02; Table 3). Patients who
had received an initial autologous HSCT transplant
had a RR of 9%, versus 29% for patients who received
an initial allogeneic HSCT (P  .36). The RR for the
5 patients who received their second HSCT 6
months from their ﬁrst transplantation was 80%,
compared with 25% for those who underwent trans-
plantation 6 months from their ﬁrst transplantation
(P  .03). None of these 5 patients received systemic
chemotherapy before their second transplantation (1
patient with CNS relapse received intrathecal chemo-
therapy only).
Five of the 13 deaths were due to NRM, with a
cumulative incidence of 20%. Three patients died
before day 100: 2 of RRT (VOD) and 1 of CMV
pneumonia. Thus, of the 22 patients who survived
100 days, 2 died of NRM (9%), 1 died of CMV
pneumonia (day 136), and 1 died of idiopathic CNS
thrombosis (day 135). NRM was similar in the pa-
tients who underwent transplantation in remission or
relapse. NRM after second HSCT in the patients who
had an initial autologous HSCT was 9%, compared
with 29% in allogeneic HSCT recipients (P  .22).
The 12 living patients all had Karnofsky performance
status or Lansky play performance scores of 90%
when assessed at a median of 7.6 years (range, 5.2-12.1
years) after the second HSCT.
Prognostic Factors for Relapse and DFS in Second
HSCT. The results from univariate Cox regression
analyses for relapse and DFS are shown in Table 4.
We evaluated the signiﬁcance of disease phase at sec-
ond HSCT, time from ﬁrst to second HSCT, time to
relapse, presence of acute or chronic GVHD, and
donor type at ﬁrst and second HSCT for relapse and
death or relapse (the complement of DFS). The pres-
ence of disease at the time of second HSCT was
signiﬁcantly associated with an increased risk of re-
lapse after HSCT (relative risk, 7.5; P  .03) and for
worse DFS (relative risk for death or relapse, 3.3; P 
.05). Also, patients who underwent transplantation6
months after the initial HSCT had a higher RR com-
pared with patients who underwent transplantation
6 months from their initial HSCT (relative risk of
relapse, 4.8; P .03). Time from ﬁrst HSCT to re-
lapse, presence of acute or chronic GVHD after sec-
ond HSCT, donor type, and age at ﬁrst or second
HSCT were not statistically associated with relapse or
DFS. Multivariate analysis revealed that disease status
at second HSCT (RR, 7.8; P  .02) and time from
ﬁrst to second HSCT of6 months (RR, 5.2; P .03)
are independent prognostic factors for relapse in pa-
tients who undergo a second HSCT.
DISCUSSION
HSCT has become a standard part of treatment of
pediatric AML. However, the RR remains high after
this aggressive therapy. Patients who relapse after an
initial HSCT pose a therapeutic dilemma because less
Table 4. Univariate Cox Regression for Relapse and Death or Relapse
Factor
Relapse Death or Relapse*
Hazard Ratio P Value† 95% CI Hazard Ratio P Value† 95% CI
Phase at second HSCT
Remission 1.0 — — 1.0 — —
Relapse 7.5 .03 0.9-60.2 3.3 .05 0.9-11.8
Time to second transplantation (mo)
>6 1.0 — — 1.0 — —
<6 4.8 .03 1.3-18.4 2.2 .21 0.7-7.2
Donor at first transplantation
Autologous 1.0 — — 1.0 — —
Allogeneic 1.9 .36 0.5-7.6 2.3 .14 0.7-7.3
Time to relapse (mo)
>6 1.0 — — 1.0 — —
<6 1.4 .61 0.4-5.2 0.9 .76 0.3-2.5
Acute GVHD
No 1.0 — — 1.0 — —
Yes 0.5 .37 0.1-2.0 1.2 .81 0.4-3.7
CI indicates conﬁdence interval.
*Complement of DFS.
†Two-sided P value from the likelihood ratio test.
S. Meshinchi et al.
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than a third achieve a remission after reinduction
chemotherapy [40], and the probability of a durable
remission with chemotherapy alone is remote. Unfor-
tunately, second HSCT for the treatment of relapsed
disease poses several barriers. The toxicity of the con-
ditioning regimen of the second HSCT is a signiﬁcant
concern [19]. However, although there are very few
pediatric data on second HSCT, the scant pediatric
data that are available have demonstrated lower RRT
in children who undergo a second HSCT. The very
low rate of toxicity after second HSCT in the pediat-
ric population reported in our current study supports
our past work and strongly suggests a basic biologic
difference regulated by age that accounts for the abil-
ity of younger individuals to tolerate high-dose pre-
parative regimens.
The improved outcome of these pediatric patients
compared with those of earlier studies may be multi-
factorial. First, given the high RRT leading to poor
outcome of second HSCT in the previous studies,
selection bias may contribute to the referral of only
the patients at low risk of RRT for second HSCT,
because patients with hepatic, renal, or pulmonary
complications are not referred for second HSCT. Sec-
ond, children are less likely to have preexisting comor-
bid conditions, such as renal or hepatic dysfunction,
that would enable them to better tolerate the condi-
tioning regimens. In addition, supportive measures,
particularly those preventing CMV and fungal infec-
tions, may ameliorate NRM [41]. Finally, HSCT reg-
imens in our previous study were TBI based and were
followed by chemotherapy-only regimens, whereas in
this study, patients received BU/CY for their initial
HSCT, followed by a TBI regimen for the second
HSCT. It may be that this order of regimens is better
tolerated. Thus, current second HSCT recipients may
experience a superior outcome regardless of the ad-
vances in supportive care or preparative regimens.
These data demonstrate that second HSCT is well
tolerated in pediatric patients without signiﬁcant tox-
icities and support second HSCT as a viable option
for the treatment of pediatric patients with AML who
relapse after an initial HSCT. Given that use of au-
tologous HSCT is declining in pediatrics, the ques-
tion arises whether there is a beneﬁt from a second
allogeneic HSCT in patients who have experienced
treatment failure with an initial allogeneic HSCT. In
this study, 14 patients received allogeneic HSCT for
both transplants from the same donors. The data show
that patients who had an initial allogeneic HSCT had
a higher NRM, higher RR, and worse OS than the
patients who had an initial autologous HSCT. Despite
such a difference, more than one third of these pa-
tients are long-term survivors, and the patients who
received their transplant in remission seemed to have
a better outcome. Thus, despite the initial transplant
type, because patients who undergo transplantation in
remission have an improved outcome, every effort
should be made to induce remission before the second
HSCT. Furthermore, in addition to the disease state,
the interval from the initial to the second HSCT
seems to be a signiﬁcant predictor of relapse. The
increased incidence may in part be explained by the
fact that most patients with early relapse who did not
receive induction therapy (and underwent transplan-
tation in relapse) are in this category and may be at
particularly high risk of relapse and poor outcome.
However, in the multivariate model taking disease
state and time from ﬁrst to second HSCT into ac-
count, the time to second transplantation continued to
be an independent risk factor for relapse.
Although remission induction in patients who re-
lapse after transplantation may be a difﬁcult task,
newer, targeted therapies provide promise for such
patients. Monoclonal antibody–mediated chemother-
apy with gemtuzumab ozogamicin (Mylotarg; Wyeth,
Princeton, NJ) has recently been used in AML pa-
tients with resistant disease [42] and may be a useful
tool in treating patients who relapse after an initial
HSCT before their second HSCT. Furthermore,
small-molecule inhibitors are showing promise in
treating patients with refractory relapsed AML [43].
However, patients who do not respond to reinduction
therapy may still beneﬁt from a second HSCT be-
cause one third of these patients are long-term survi-
vors, whereas patients without HSCT have a dismal
outcome. Given the acceptable toxicity of the second
transplantation and the encouraging outcomes for pa-
tients in this study, we recommend that pediatric pa-
tients with AML who relapse after an initial HSCT be
considered for a second transplantation after an initial
attempt at remission induction.
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